Literature DB >> 15833798

Tempol therapy attenuates medial smooth muscle cell apoptosis and neointima formation after balloon catheter injury in carotid artery of diabetic rats.

D K Jagadeesha1, Timothy E Lindley, Jason Deleon, Ram V Sharma, Francis Miller, Ramesh C Bhalla.   

Abstract

Accumulating data support the hypothesis that reactive oxygen species (ROS) play a critical role in the vascular complications observed in diabetes. However, the mechanisms of ROS-mediated vascular complications in diabetes are not clear. We tested the hypothesis that ROS-mediated increase in proapoptotic factor Bax expression leads to medial smooth muscle cell (SMC) apoptosis that is associated with neointima formation. We used a fructose-rich diet for 4 wk to model Type 2 diabetes in rats. SOD mimetic membrane-permeable 4-hydroxy-2,2,6,6,-tetramethylpiperidine-1-oxyl (Tempol, 1 mM) was administered in drinking water to scavenge superoxide starting 1 day before surgery and continued during the duration of the experiment. Vascular injury resulted in a significant increase in medial SMC apoptosis that was associated with neointima formation. The number of medial SMC positive for Bax immunostaining significantly increased in injured arteries compared with uninjured arteries. Superoxide scavenging by Tempol treatment inhibited both the Bax-positive index as well as the apoptotic index of medial SMC in response to vascular injury. Tempol treatment inhibited apoptotic loss of medial SMC, thus increasing their density in the injured arteries. These alterations in the media were associated with a marked decrease in neointima formation in injured arteries. We conclude that Bax expression may play an important role in vascular SMC apoptosis and, finally, that this regulatory mechanism is redox sensitive.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15833798     DOI: 10.1152/ajpheart.01071.2004

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  17 in total

Review 1.  Vascular oxidative stress: the common link in hypertensive and diabetic vascular disease.

Authors:  Richard A Cohen; XiaoYong Tong
Journal:  J Cardiovasc Pharmacol       Date:  2010-04       Impact factor: 3.105

2.  Effect of a single, open-sea, air scuba dive on human micro- and macrovascular function.

Authors:  Kate Lambrechts; Jean-Michel Pontier; Costantino Balestra; Aleksandra Mazur; Qiong Wang; Peter Buzzacott; Michael Theron; Jacques Mansourati; François Guerrero
Journal:  Eur J Appl Physiol       Date:  2013-08-15       Impact factor: 3.078

3.  Genetic interleukin-10 deficiency causes vascular remodeling via the upregulation of Nox1.

Authors:  Jagadeesha K Dammanahalli; Xiuqing Wang; Zhongjie Sun
Journal:  J Hypertens       Date:  2011-11       Impact factor: 4.844

4.  Nox1 transactivation of epidermal growth factor receptor promotes N-cadherin shedding and smooth muscle cell migration.

Authors:  Dammanahalli K Jagadeesha; Maysam Takapoo; Botond Banfi; Ramesh C Bhalla; Francis J Miller
Journal:  Cardiovasc Res       Date:  2011-11-18       Impact factor: 10.787

Review 5.  Effects of tempol and redox-cycling nitroxides in models of oxidative stress.

Authors:  Christopher S Wilcox
Journal:  Pharmacol Ther       Date:  2010-02-11       Impact factor: 12.310

6.  Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.

Authors:  Paras K Mishra; Neetu Tyagi; Utpal Sen; Irving G Joshua; Suresh C Tyagi
Journal:  Cardiovasc Diabetol       Date:  2010-09-09       Impact factor: 9.951

7.  High glucose oxidizes SERCA cysteine-674 and prevents inhibition by nitric oxide of smooth muscle cell migration.

Authors:  Xiaoyong Tong; Jia Ying; David R Pimentel; Mario Trucillo; Takeshi Adachi; Richard A Cohen
Journal:  J Mol Cell Cardiol       Date:  2007-11-12       Impact factor: 5.000

Review 8.  Redox control of vascular smooth muscle migration.

Authors:  Alejandra San Martín; Kathy K Griendling
Journal:  Antioxid Redox Signal       Date:  2010-03-01       Impact factor: 8.401

9.  Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome.

Authors:  Sadaf S Ahanchi; Vinit N Varu; Nick D Tsihlis; Janet Martinez; Charles G Pearce; Muneera R Kapadia; Qun Jiang; Joseph E Saavedra; Larry K Keefer; Joseph A Hrabie; Melina R Kibbe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-17       Impact factor: 4.733

10.  Emerging role for antioxidant therapy in protection against diabetic cardiac complications: experimental and clinical evidence for utilization of classic and new antioxidants.

Authors:  Michael F Hill
Journal:  Curr Cardiol Rev       Date:  2008-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.